Pfizer Inc. (NYSE: PFE) currently offers one of the juiciest dividend yields in the U.S. stock market at 6.7%, a figure that far outpaces the S&P 500’s meager 1.1% average. For income-focused investors, this translates to nearly $1,700 in annual dividend income from a $25,000 investment—more than five times the less than $300 generated by an average S&P 500 stock. However, this attractive payout is facing unprecedented scrutiny, with its sustainability emerging as a heated debate on Wall Street following the company’s latest earnings release.
Pfizer’s first-quarter 2026 results, released earlier this month, cast a long shadow over its dividend policy. While the company delivered a modest 5% year-over-year revenue increase, its net income fell 9%, with adjusted net income plunging an even steeper 18%. This earnings deterioration has triggered immediate concerns among dividend investors, who rely on consistent profitability to support regular payouts.
Two critical metrics tell a worrying story. Pfizer reported earnings per share (EPS) of $0.47 in the quarter, barely exceeding its $0.43 quarterly dividend. This means the company is paying out more than 91% of its earnings as dividends, well above the 50%-70% range considered safe for the pharmaceutical industry. Even more alarming is the cash flow situation: Pfizer generated just $2.2 billion in free cash flow during the period, insufficient to cover its $2.4 billion quarterly dividend obligation. While cash flow can fluctuate quarter-to-quarter, this gap represents a significant red flag for income investors.
Beneath these short-term financial pressures lie deeper structural crises. During the pandemic, Pfizer’s COVID-19 vaccine and antiviral treatment propelled annual revenue above $100 billion. But that windfall has evaporated: COVID-related revenue collapsed from $56.7 billion in 2022 to $6.7 billion in 2025, and management expects it to fall further to approximately $5 billion in 2026. Compounding this challenge is an impending patent cliff: between 2026 and 2030, blockbuster drugs including Eliquis and Ibrance will lose exclusivity, allowing generic competitors to erode market share. Pfizer estimates that patent expirations alone will reduce its 2026 revenue by roughly $1.5 billion.
To counter these headwinds, Pfizer has embarked on an aggressive transformation strategy centered on acquisitions, oncology expansion, and pipeline development. The cornerstone of this effort is its acquisition of Seagen, a leader in antibody-drug conjugates—an emerging class of targeted cancer therapies widely viewed as one of the pharmaceutical industry’s most promising long-term growth markets. The deal was designed not for immediate revenue gains, but to rebuild Pfizer around oncology for the next decade.
Today, oncology accounts for approximately 27% of Pfizer’s total revenue, with products such as Padcev, Xtandi, and Lorbrena helping offset declining COVID sales. The company reported that its recently launched and acquired products generated $10.2 billion in revenue in 2025, representing a 14% year-over-year increase on an operational basis. Pfizer’s management has reaffirmed its commitment to maintaining the current dividend, arguing that ongoing cost-cutting measures and synergies from recent acquisitions will gradually improve profitability and strengthen the payout’s sustainability.
From a valuation perspective, Pfizer remains compelling. Its stock has fallen more than 60% from pandemic-era highs, and it currently trades at less than 9 times forward earnings, making it one of the cheapest large-cap pharmaceutical stocks available. However, analysts caution that a dividend cut cannot be ruled out if Pfizer’s financial performance fails to improve significantly while it continues to pursue strategic acquisitions.
For investors, Pfizer in 2026 is neither a screaming buy nor a clear sell—it is best characterized as a hold. This mature pharmaceutical giant is navigating a painful transition period, offering generous dividends to compensate shareholders for their patience. If management successfully executes its oncology strategy, today’s low valuation could prove to be a bargain. But if legacy drug revenue declines outpace the growth of new products, Pfizer’s stock could remain stuck in neutral for years to come.
